Evidence map›Paper›PMID 42547588›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

G protein signaling capabilities at the bradykinin 2 receptor.

Shradha V Darira, Laurie P Sutton

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Shradha V DariraDepartment of Biological Sciences, University of Maryland Baltimore County, Baltimore, MD, 21250, USA.
Laurie P SuttonDepartment of Biological Sciences, University of Maryland Baltimore County, Baltimore, MD, 21250, USA. suttonl@umbc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The bradykinin 2 receptor (B2R) is one of two members of the kinin receptor family and is a G protein-coupled receptor (GPCR) that regulates important physiological processes including pain, inflammation, and cardiovascular homeostasis. Functionally, B2R is activated by the kinin peptides, bradykinin and kallidin. Carboxypeptidase cleavage of bradykinin and kallidin results in the formation of des-Arg9-bradykinin (DABK) and des-Arg10-kallidin (DAKD) respectively, which are classically described as agonists of the bradykinin 1 receptor (B1R), the other member of the kinin family. Affinity binding studies have reported that DABK and DAKD can also bind to B2R. Upon activation, B2R signals through the recruitment of heterotrimeric G proteins, and earlier work has highlighted the promiscuous G protein coupling to B2R in response to bradykinin. However, a comprehensive G protein activation profile of the B2R receptor when activated by the other endogenous agonists has not yet been established. In this study, we used Bioluminescence Resonance Energy Transfer (BRET)-based in vitro assays to monitor the coupling of 14 different Gα proteins upon B2R activation. Our results show that there is a shift in G protein activation profiles and kinetics among the different peptides. By analyzing responses across a range of agonist concentrations, we further identified biased signaling among these peptides, with differential activation of specific Gα subtypes. These results improve understanding of intracellular mechanisms through which the kinin system regulates different aspects of its physiological role and provide valuable information for the design of drugs targeting the kinin receptors.

Indexed as

Bias signalingBradykininG proteinG protein–coupled receptor

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.